All In Biotech

Drug Trial Radar · NCT07823205

A Study to Evaluate Different Oral Formulations of KT-621

A Phase 1, Open-Label, Crossover Study to Evaluate the Relative Bioavailability of Different Oral Formulations of KT-621 in Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Oct 5, 2026

Primary completion

Apr 2027

Study completion May 2027

Sponsor

Lead sponsor
Kymera Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase I study to evaluate the relative bioavailability and safety and tolerability of different oral formulations of KT-621 in healthy adult participants.

Conditions

  • Healthy Participants

Interventions

  • KT-621Drug

    KT-621 Reference Oral Formulation

  • KT-621Drug

    KT-621 Test Oral Formulation #1

  • KT-621Drug

    KT-621 Test Oral Formulation #2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Plasma Concentration (Cmax) of KT-621Time frame: Day 1 through Day 24 (Part A); Day 1 through Day 30 (Part B)
  2. Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of KT-621Time frame: Day 1 through Day 24 (Part A); Day 1 through Day 30 (Part B)
  3. Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC∞) of KT-621Time frame: Day 1 through Day 24 (Part A); Day 1 through Day 30 (Part B)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion

    Lincoln, Nebraska · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.